Overview

A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

Status:
Terminated
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
EMD Serono decided to terminate enrollment based on a review of the available clinical data and low probability of completing the trial based on the observed recruitment rate. Subjects already enrolled in the study continued participation in the study, consistent with the protocol, to study completion.
Phase:
Phase 1
Details
Lead Sponsor:
EMD Serono